US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

14.02

+0.45003.32%

Volume:326.55K

Turnover:4.57M

Market Cap:508.82M

PE:-5.37

High:14.25

Open:13.74

Low:13.70

Close:13.57

52wk High:33.20

52wk Low:10.47

Shares:36.29M

Float Shares:19.98M

Volume Ratio:0.79

T/O Rate:1.63%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.83

PE(LYR):-1.25

Loading ...

Overview Company News Filings

Evommune announces annual shareholder meeting via virtual webcast

BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC Filing

Evommune Inc - Prospectus Filed for Resale of up to 4.5 Mln Shares of Evommune Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT)

Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating

Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy

Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says

MT Newswires Live

Evommune Price Target Maintained With a $48.00/Share by RBC Capital

Evommune assumed with an Outperform at Oppenheimer

Evommune to host webinar on MRGPRX2 inhibition potential in migraine

Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise

Evommune price target lowered to $50 from $65 at H.C. Wainwright

Evommune Initiated at Buy by Clear Street

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Evommune initiated with a Buy at Clear Street

Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst

Evommune Reports Q4 2025 Results and Pipeline Progress

Evommune reports Q4 EPS ($1.43), consensus (84c)

Evommune Q4 EPS $(1.43) Misses $(0.74) Estimate

Benzinga Earnings

Evommune FY 2025 revenue rises to USD 13.0 million (85.7%)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/EVMN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":14.02,"timestamp":1787342400000,"preClose":13.57,"halted":0,"volume":326552,"delay":0,"changeRate":0.033161385408990364,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Pre-Mkt","change":0.45,"latestTime":"08-24 06:40:29 EDT","open":13.74,"high":14.25,"low":13.7,"amount":4565526.77752,"amplitude":0.040531,"askPrice":16.39,"askSize":100,"bidPrice":11.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":14.02,"postHourTrading":{"tag":"盘后","latestPrice":14.02,"preClose":14.02,"latestTime":"19:32 EDT","volume":5950,"amount":83404.12,"timestamp":1787355127959,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7864220387572776,"impliedVol":1.4355,"impliedVolPercentile":0.7024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":0.7864220387572776,"shares":36292113,"dividePrice":0,"high":14.25,"amplitude":0.040531,"preClose":13.57,"low":13.7,"week52Low":10.47,"pbRate":"1.83","psRate":"50.88","week52High":33.2,"institutionHeld":0,"latestPrice":14.02,"eps":-2.609,"divideRate":0,"volume":326552,"delay":0,"ttmEps":-2.609,"open":13.74,"prevYearClose":17.12,"prevWeekClose":14.02,"prevMonthClose":11.25,"prevQuarterClose":13.29,"fiveDayClose":14.65,"twentyDayClose":11.36,"sixtyDayClose":23.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1782878400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-08-21","current":-5.373706,"percent":0.994975,"low":-16.229076,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"high":-5.090694,"avg":-9.990083,"sd":2.778399,"marketCap":492483973},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973}],"updateTime":1787565156083},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629057232","title":"Evommune announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057232?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:06","pubTimestamp":1776802016,"startTime":"0","endTime":"0","summary":"Evommune schedules annual stockholders meeting for June 2, 2026, held virtually.Shareholders will vote to elect two Class I directors: Luis Pea, Eugene A. Bauer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3xTnW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628492784","title":"BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628492784","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628492784?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:40","pubTimestamp":1776458421,"startTime":"0","endTime":"0","summary":"BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC FilingApril 17  - Evommune Inc EVMN.N:EVOMMUNE INC - PROSPECTUS FILED FOR RESALE OF UP TO 4.5 MILLION SHARES OF EVOMMUNE COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text: []Further company coverage: EVMN.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nFWN4100KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628814207","title":"Evommune Inc - Prospectus Filed for Resale of up to 4.5 Mln Shares of Evommune Common Stock by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628814207","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628814207?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:07","pubTimestamp":1776456431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nFWN4100KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277083","title":"Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628277083?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:20","pubTimestamp":1776421208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evommune, Inc. (EVMN) and Sarepta Therapeutics (SRPT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-evommune-inc-evmn-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-evommune-inc-evmn-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SRPU","IE0009355771.USD","BK4588","BLSG","XBI","SRPT","LU0128526141.USD","BK4112","BK4581","IE00BJJMRZ35.SGD","LU0029874061.USD","IE00BJT1NW94.SGD","BLSX","IE0002141913.USD","EVMN","IE00B2B36J28.USD","BK4139","LABU","IE00BFTCPJ56.SGD","BK4585","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627888469","title":"Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2627888469","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627888469?lang=en_us&edition=fundamental","pubTime":"2026-04-14 05:35","pubTimestamp":1776116121,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on April 10. Matt Phipps has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-differentiated-mrgprx2-strategy-and-upcoming-evo756-phase-iib-readout-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-differentiated-mrgprx2-strategy-and-upcoming-evo756-phase-iib-readout-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627654004","title":"Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627654004","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627654004?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:36","pubTimestamp":1776112583,"startTime":"0","endTime":"0","summary":"An update from Evommune, Inc. ( ($EVMN) ) is now available. On April 13, 2026, Evommune hosted a webcast detailing the migraine treatment landscape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-spotlights-evo756-as-novel-preventive-migraine-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-spotlights-evo756-as-novel-preventive-migraine-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626791119","title":"Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2626791119","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626791119?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:45","pubTimestamp":1775835923,"startTime":"0","endTime":"0","summary":"Evommune's  experimental drug for chronic hives may have broader uses if upcoming trial results show it's both safe and effective, RBC Capital Markets said Friday in a report.The company's MRGPRX2 antagonist EVO756 has about a 50% chance of working on chronic spontaneous urticaria, or CSU, based on early signs that it reaches the right tissues and hits its intended target, RBC said. There's no direct CSU data yet, though the drug's exposure levels and results from a related challenge test support optimism, the report said.If the CSU study reads out positively later this quarter, RBC said EVO756 may also be tested in other conditions linked to overactive immune cells, including migraine, interstitial cystitis, and other inflammatory disorders. The CSU market is estimated at $850 million, with migraine representing a larger commercial opportunity, the report said.Some investor skepticism persists around EVO756, though its early data and tissue-targeting signals support for a more constru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626115427","title":"Evommune Price Target Maintained With a $48.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2626115427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626115427?lang=en_us&edition=fundamental","pubTime":"2026-04-10 22:13","pubTimestamp":1775830380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 10:13 ET (14:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625524959","title":"Evommune assumed with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625524959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625524959?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:18","pubTimestamp":1775571481,"startTime":"0","endTime":"0","summary":"Oppenheimer assumed coverage of Evommune (EVMN) with an Outperform rating and $50 price target The firm says investor focus is on Q2 readout in chr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671703","title":"Evommune to host webinar on MRGPRX2 inhibition potential in migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671703?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480450,"startTime":"0","endTime":"0","summary":"Evommune will host a KOL webinar on April 13, 2026 at 11:00 a.m. PT  focused on migraine treatment landscape and MRGPRX2 inhibition.Webinar will feature presentations from Stewart Tepper and Greg Dussor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire  on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL4czBty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620341552","title":"Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2620341552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620341552?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:16","pubTimestamp":1773828963,"startTime":"0","endTime":"0","summary":"Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Evommune, Inc.. The associated price target was lowered to $50.00. M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-buy-rating-backed-by-2026-catalyst-rich-pipeline-and-differentiated-mrgprx2-dermatology-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-buy-rating-backed-by-2026-catalyst-rich-pipeline-and-differentiated-mrgprx2-dermatology-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620234436","title":"Evommune price target lowered to $50 from $65 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234436?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:12","pubTimestamp":1773828734,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Evommune (EVMN) to $50 from $65 and keeps a Buy rating on the shares. The firm cites the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-50-from-65-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-50-from-65-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620239235","title":"Evommune Initiated at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2620239235","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620239235?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:35","pubTimestamp":1773826500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 05:35 ET (09:35 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1923621640.USD","APGE","GEMI","FDS","LU2360107671.USD","STZ","CLH","CTMX","DUOL","BL","GEMG","CCL","BTSG","CALM","EQIX","CADL","FICO","XYZG","ECL","ANDG","BTGO","BKKT","ASO","DC","GHM","DOCU","DTE","EVMN","CE","ANRO","CLYM","LU1992135472.HKD","XYZ","IE00BMG7P926.USD","DLR","HQY","CF","ARCT","ALDX","AJG","CRC","GLGG","ETR","GLXU","XYZY","COHX","APD","DOW","COHR","GLXY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620140318","title":"Evommune initiated with a Buy at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2620140318","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620140318?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:25","pubTimestamp":1773779128,"startTime":"0","endTime":"0","summary":"Clear Street initiated coverage of Evommune (EVMN) with a Buy rating and $53 price target The firm views “first-in-class” oral EVO756 offering “an ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-initiated-with-a-buy-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-initiated-with-a-buy-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617563681","title":"Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2617563681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617563681?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:35","pubTimestamp":1772807724,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Smith from Leerink Partners reiterated a Buy rating on Evommune, Inc., with a price target of $52.00. According ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evommune-inc-evmn-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evommune-inc-evmn-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579225","title":"Evommune Reports Q4 2025 Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579225?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:40","pubTimestamp":1772746820,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ( ($EVMN) ) just unveiled an announcement. Evommune, Inc. reported its fourth quarter and full-year 2025 results on March 5, 2026, h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-reports-q4-2025-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-reports-q4-2025-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","EVMN","BK4139","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617157601","title":"Evommune reports Q4 EPS ($1.43), consensus (84c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617157601","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617157601?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:06","pubTimestamp":1772744771,"startTime":"0","endTime":"0","summary":"“The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune (EVMN) and further validates IL-18 inhibition as a compel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-reports-q4-eps-1-43-consensus-84c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-reports-q4-eps-1-43-consensus-84c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575287","title":"Evommune Q4 EPS $(1.43) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575287","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575287?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744724,"startTime":"0","endTime":"0","summary":"Evommune (NYSE:EVMN) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(0.74) by 91.95 percent. This is a 89.47 percent increase over losses of $(13.58) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51082703/evommune-q4-eps-1-43-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune Q4 EPS $(1.43) Misses $(0.74) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575914","title":"Evommune FY 2025 revenue rises to USD 13.0 million (85.7%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575914?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744508,"startTime":"0","endTime":"0","summary":"Evommune FY 2025 revenue rises to USD 13.0 million (85.7%)               Evommune reported Q4 FY2025 net loss of USD 28.3 million and FY2025 net loss of USD 68.9 million. Q4 FY2025 R&D expenses were U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL6j8BHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":84,"code":"91000000","status":"200"}]}}